Showing results (1-10 of 204) with videos related to
Sort By:
Pageof 21
The Journal of Infusional Chemotherapy|July 1, 1996
CPT-11: the European clinical developmentC Terret, C Couteau, J P ArmandAnnals of the New York Academy of Sciences|December 13, 1996
CPT-11. The European experienceJ P Armand, C Terret, C Couteau, et al.Bulletin Du Cancer|January 1, 1996
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials]C Couteau, K Yakendji, C Terret, et al.Bulletin Du Cancer|February 5, 1999
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas]C Couteau, J P ArmandAnnals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patientsE Cellarier, C Terret, P Labarre, et al.Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2010
[Definition and outline on geriatric oncology]C Terret, J-P DrozEuropean Review for Medical and Pharmacological Sciences|November 20, 2020
Soap and syndets: differences and analogies, sources of great confusionL Coiffard, C CouteauJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I studyG G Chabot, J P Armand, C Terret, et al.British Journal of Cancer|October 3, 1999
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neckC Couteau, N Chouaki, S Leyvraz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumorsC Couteau, M L Risse, M Ducreux, et al.Pageof 21